OracleBio will be attending the Immune Checkpoint Inhibitors Boston Conference, which runs from the 14th to the 16th of March 2017.
OracleBio offers a range of digital pathology image analysis services to support pre-clinical and clinical immuno-oncology R&D and have generated data as part of immune checkpoint inhibitor studies. In one recently published study, we performed digital image analysis for quantification of CD8+T-cells in a mouse syngeneic model to demonstrate the potential of a checkpoint inhibitor combination therapy. OracleBio’s Business Development Manager, Matt Gaffney, will be at ICI Boston to discuss this case study, as well as other immune checkpoint inhibitor studies, in more detail.
Returning for its 3rd year, ICI Boston 2017 address key issues in the immuno-oncology field and provides comprehensive insights into immune checkpoint development. The conference focuses on delivering maximum clinical benefit through immune checkpoint monotherapy and combinations, from pathway validation to clinical success. To find out more about ICI Boston, please click here.
If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with Matt during the conference, please contact us.
To keep up to date with all OracleBio news, please follow us on LinkedIn by clicking on the button below: